The physiologically active form of vitamin D 3 , 1 ,25-dihydroxyvitamin D 3 , is a potent inducer of cell diVerentiation in several isolated and established cancer cell lines. 1 2 In addition, epidemiological studies suggest that vitamin D 3 protects against the development of colon cancer. 1 3 In vitro studies using human colorectal epithelial explants indicate that colonic tissue can respond to the active metabolite of vitamin D 3 . 4 The clinical use of 1 ,25-dihydroxyvitamin D 3 is limited by its profound aVects on calcium metabolism. 4 5 Synthetic vitamin D 3 analogues with a more favourable therapeutic ratio than 1 ,25-dihydroxyvitamin D 3 have recently been developed. 6 Calcipitriol (a synthetic analogue) retains potent cell cycle regulatory properties with reduction of hypercalcaemic and hypercalciuric side eVects. 7 Calcipitriol is an eVective topical treatment for psoriasis and also reduces human colorectal epithelial cell proliferation in vitro. 8 9 This agent, however, is not suitable for systemic use because of its short half life, with rapid elimination from the body and the formation of metabolites with low biological activity. 10 In contrast, the analogue EB1089 is a potent antiproliferative agent following systemic administration in animal models.
11
Vitamin D 3 analogues appear to bind to a specific high aYnity nuclear receptor protein which belongs to the superfamily of steroid receptors. 12 13 Receptor-hormone complexes bind to vitamin D response elements in the promoter regions of the primary vitamin D response genes, leading to activation or suppression of gene transcription. [13] [14] [15] Vitamin D receptor appears to bind to response elements either as a homodimer or as a heterodimer with other nuclear receptors such as retinoid X, retinoic acid, and the thyroid hormone receptors. 15 16 Receptor binding studies have demonstrated the presence of the vitamin D receptor in human colorectal cancer tissue, although the level of expression is disputed. 16 17 We have used a monoclonal antibody to study vitamin D receptor expression in human colorectal cancer tissue to determine if receptor expression is influenced by the Dukes' stage of tumour or the degree of cellular differentiation.
Methods
We selected an unbiased cohort of paraYn embedded archival tissue from 30 patients with primary colorectal carcinoma. The degree of diVerentiation was reported as well diVerentiated (G 1 ) in three, moderately well diVerentiated (G 2 ) in 19, and poorly diVerentiated (G 3 ) in eight of these tumours. Tissues were also classified according to stage of disease: Dukes' A (n = 10), Dukes' B (n = 11), and Dukes' C (n = 9). Sections (3 µm thick) were dewaxed in xylene and rehydrated through decreasing concentrations of alcohol. Endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in methanol and the tissue was hydrolysed in 2 M HCl at 37°C for 30 minutes. Non-specific antibody binding was blocked with normal goat serum for 20 minutes.
The primary 9A7 IgG 2b monoclonal antibody directed against the vitamin D receptor (Chemicon International) was added using a 1:50 solution in Tris buVered saline (TBS) for two hours at room temperature. 18 The second layer was a biotinylated goat IgG antibody (Biogenex) at a concentration of 1:20 in TBS. The third layer was horseradish peroxidase labelled streptavidin (Biogenex) at a concentration of 1:20 in TBS.
Slides were developed with diaminobenzidine (250 µg with 0.037% H 2 O 2 ) to demonstrate peroxidase activity, and counterstained with haematoxylin. Breast and kidney tissue are known to express vitamin D receptors and were therefore used as positive controls.
19-21 TBS buVer was substituted for the primary antibody as a negative control. An avidin/biotin complex blocking kit (Vector Laboratories) was used with the blocking serum and primary antibody to block endogenous avidin and biotin. Specificity of the staining reaction was verified by substituting rat IgG for the monoclonal antibody on the control slides.
Immunohistochemical staining was assessed semiquantitatively by two independent observers and the mean number of cells showing strong nuclear staining was determined per graticule square at ×400 magnification in 20 separate fields. The means of the median and range of scores for nuclear staining were calculated for each tissue section, and compared between groups of patients with Dukes' stage and degree of diVerentiation.
Results
Vitamin D receptor staining was located predominately in the nuclei of positively reacting cells, with very little cytoplasmic staining (fig 1) . A striking gradation in immunoreactivity was seen in microscopically normal colonic crypts, the immunoreactivity being predominantly in the mid and upper crypts only. 
